Literature DB >> 1164007

Gentamicin blood levels: a guide to nephrotoxicity.

J G Dahlgren, E T Anderson, W L Hewitt.   

Abstract

Gentamicin blood levels were monitored in 86 patients. Twenty-one patients had valley levels over 2 mug/ml and 36% of these patients developed abnormal serum creatinine or a further rise in creatinine. No patient had a rise in creatinine without a valley level over 2. The peak levels in patients with valleys over 2 were above 10 mug/ml in only one case, whereas four patients had peaks over 10 mug/ml without nephrotoxicity. The mean peak blood levels in patients with a normal creatinine were dose related. An initial dose of 2.0, 1.5, and 1.3 or less mpk (mg/kg) yielded mean peak blood levels of 5.2, 4.7, and 3.7, respectively. To assure an initial peak blood level over 4 mug/ml a loading dose of 2 mpk was required. A rise in peak and valley levels during therapy appeared dose related, being observed in all patients treated with 4.5 mpk daily but not in those receiving 3.0 mpk daily. A radioenzymatic assay was used to validate the standard agar diffusion assay method. The results from the two assays were statistically identical. Valley blood levels of gentamicin may be useful for predicting accumulation of gentamicin which in turn may be correlated with early renal impairment before potentially toxic serum levels of gentamicin develop.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1164007      PMCID: PMC429261          DOI: 10.1128/AAC.8.1.58

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  A rapid chemical assay for gentamicin.

Authors:  D H Smith; B Van Otto; A L Smith
Journal:  N Engl J Med       Date:  1972-03-16       Impact factor: 91.245

2.  Correlation of serum creatinine concentration and gentamicin half-life.

Authors:  R E Cutler; A M Gyselynck; W P Fleet; A W Forrey
Journal:  JAMA       Date:  1972-02-21       Impact factor: 56.272

3.  Possible nephrotoxicity of gentamicin.

Authors:  R G Schultze; R E Winters; H Kauffman
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

4.  Renal insufficiency associated with gentamicin therapy.

Authors:  J N Wilfert; J P Burke; H A Bloomer; C B Smith
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

5.  Pharmacology of gentamicin in man.

Authors:  L J Riff; G G Jackson
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

6.  Pharmacokinetics of gentamicin: distribution and plasma and renal clearance.

Authors:  A M Gyselynck; A Forrey; R Cutler
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

7.  Relation between dose and levels of gentamicin in blood.

Authors:  R E Winters; K D Litwack; W L Hewitt
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

8.  Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin.

Authors:  G G Jackson; L J Riff
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

  8 in total
  68 in total

Review 1.  Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.

Authors:  R C Li; M Zhu; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

2.  Serum levels of gentamicin at peak and trough in neonates and infants.

Authors:  M Shahidullah; M Q Talukder; A K Chowdhury; S Ali; A Rashid
Journal:  Indian J Pediatr       Date:  1991 Mar-Apr       Impact factor: 1.967

3.  Radioimmunoassay of iodinated tobramycin.

Authors:  A Broughton; J E Strong; L K Pickering; G P Bodney
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

4.  Failure of a nomogram to achieve target aminoglycoside concentrations.

Authors:  M W Perkins
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

5.  Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution.

Authors:  Sujata M Bhavnani; Jeffrey P Hammel; Elizabeth A Lakota; M Courtney Safir; Brian D VanScoy; Yu Nagira; Christopher M Rubino; Nobuo Sato; Tomokazu Koresawa; Kenichiro Kondo; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

6.  Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients.

Authors:  M A French; F B Cerra; M E Plaut; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

7.  Pharmacokinetic and pathological evaluation of gentamicin in cats given a small intravenous dose repeatedly for five days.

Authors:  A D Jernigan; R C Hatch; J Brown; W A Crowell
Journal:  Can J Vet Res       Date:  1988-04       Impact factor: 1.310

Review 8.  Why monitor serum levels of gentamicin?

Authors:  M Barza; M Lauermann
Journal:  Clin Pharmacokinet       Date:  1978 May-Jun       Impact factor: 6.447

9.  Influence of age on amikacin pharmacokinetics in patients without renal disease. Comparison with gentamicin and tobramycin.

Authors:  L A Bauer; R A Blouin
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 10.  Therapeutic drug monitoring of aminoglycosides in neonates.

Authors:  Daniël J Touw; Elsbeth M Westerman; Arwen J Sprij
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.